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3ABSTRACT
Background. The incidence of renal replacement therapy (RRT) in the general population aged 75
years or older varies considerably between countries and regions in Europe. Our aim was to study
characteristics and survival of elderly RRT patients, and to find explanations for differences in RRT
incidence.
Methods. Patients aged 75 years or older at the onset of RRT in 2010 to 2013, from 29 national or
regional registries providing data to the European Renal Association- European Dialysis and
Transplantation Association (ERA-EDTA) Registry, were included. Chi-square and Mann-Whitney-U
tests were used to assess variation in patient characteristics, and linear regression was used to
study the association between RRT incidence and various factors. Kaplan-Meier curves and Cox
regression were employed for survival analyses.
Results. The mean annual incidence of RRT in the age group 75 years or older ranged from 157 to
924 per million age-related population. The median age at the start of RRT was higher and
comorbidities were less common in areas with higher RRT incidence, but overall the association
between patient characteristics and RRT incidence was weak. The unadjusted survival was lower in
high-incidence areas due to higher age at onset of RRT, but the adjusted survival was similar (RR
1.00; 95% CI 0.97—1.03) in patients from low- and high-incidence areas.
Conclusions. Variation in the incidence of RRT among the elderly across European countries and
regions is remarkable and could not be explained from the available data. However, the survival of
patients in low- and high-incidence areas was remarkably similar.
Keywords: Elderly, ESRD, Europe, incidence, renal replacement therapy.
4INTRODUCTION
The European population is aging and the proportion of individuals aged 80 years or older has
increased from 3.9% in 2004 to 5.1% in 2014 [1]. Simultaneously, the number of patients on renal
replacement therapy (RRT) aged 75 years or older has nearly doubled, comprising 30% of all
patients entering RRT in Europe. However, in 2014 the incidence of RRT per million age-related
population (PMARP) among inhabitants aged 75 years or older varied considerably between
European countries, ranging from 177 in Finland to 898 in Greece[2,3]. This has raised the
question whether high incidence of RRT in the elderly population is related to widespread use of
dialysis in frail patients with multiple comorbidities and poor survival.
Elderly RRT patients have inferior survival compared with younger patients [2,4] and cognitive
decline as well as functional impairment and frailty are associated with adverse health outcomes
[5]. The probability of receiving a kidney transplant is lower in the older age groups, whereas most
elderly RRT patients are treated with in-center haemodialysis [2] which is the most expensive
treatment modality [6]. As among elderly patients with comorbidities dialysis may not provide a
survival advantage or improve health-related quality of life over conservative management of end-
stage renal disease (ESRD) [7-9], careful selection of patients who are likely to benefit from RRT is
essential.
The aim of this study was to search for explanations for the notable differences in RRT incidence in
the elderly population by studying characteristics and survival of patients starting RRT in European
countries.
MATERIALS AND METHODS
Patients aged 75 years or older who started chronic RRT between 2010 and 2013 were identified
from 13 national (Austria, Bosnia and Herzegovina, Denmark, Estonia, Finland, France, Greece,
Iceland, Norway, Romania, Serbia, Sweden, and the Netherlands) and 16 regional (Dutch- and
French-speaking Belgium, UK Scotland, and the Spanish regions of Andalusia, Aragon, Asturias,
Basque Country, Cantabria, Castile and León, Castile-La Mancha, Community of Madrid, Catalonia,
Extremadura, Galicia, Murcia, and Valencia) registries providing individual patient-level data to the
ERA-EDTA Registry. Data were only available from Bosnia and Herzegovina and Serbia in 2011—
2013, from Spain region of Murcia in 2012—2013, and from Estonia in 2013. Twelve registries
(Austria, Dutch- and French-speaking Belgium, Denmark, Finland, Iceland, Norway, Sweden, and
the Spanish regions of Aragon, Catalonia, Galicia, and Valencia) reported additional data on
comorbidities at the start of RRT. Patients aged 20—74 were selected as a control group.
The incidence PMARP was deﬁned as the number of patients starting RRT annually divided by the
mid-year age-related general population. Patients were divided into two groups according to low
5(<500 PMARP) or high (>500 PMARP) registry-level incidence of RRT in the age group of 75 years or
older. This division was selected to balance the number of patients and registries between low-
and high-incidence groups.
Demographic and clinical variables such as age, sex, primary renal disease, initial RRT modality,
survival, comorbidity (diabetes, ischemic heart disease, peripheral vascular disease,
cerebrovascular disease, and malignancy), and body mass index (BMI) at the onset of RRT were
correlated to the RRT incidence. Associations of life expectancy at birth [10] and gross domestic
product (GDP) per capita [11] with RRT incidence were analysed. The reported causes of death
were divided into eight groups, cardiovascular, cerebrovascular, infection, suicide / refusal or
withdrawal from RRT, cachexia, malignancies, miscellaneous and unknown / unavailable.
When comparing distributions of variables between low- and high-incidence RRT registries, chi-
square test was used for categorical variables and Mann-Whitney-U test for continuous variables.
Linear regression was used to assess the association between continuous variables and RRT
incidence by registry. Survival probability was assessed using the Kaplan-Meier method and
differences in survival by the log-rank test, while the relative risk of death as a function of risk
factors was estimated using Cox proportional hazards regression. Comorbidities were entered into
the model as single items. Patients from Romania were excluded from the survival analysis
because complete RRT history was not available for all patients. The survival time was calculated
from the ﬁrst day of RRT (dialysis or pre-emptive kidney transplantation) and the patients were
followed until death (N = 19 413), censoring at loss to follow-up (N = 486), recovery of renal
function (N = 1 079), or end of the follow-up period on 31 December 2014 (N = 16 632).Two-sided
P-values lower than 0.05 were considered statistically significant. Statistical analyses were
performed using IBM SPSS Statistics 23.
RESULTS
Incidence
In the European countries and regions reporting individual patient data to the ERA-EDTA Registry,
a total of 38 457 patients aged 75 years or older entered RRT between 2010 and 2013. The mean
annual incidence of RRT in the age group 75 years or older, in 2010 to 2013, was 537 PMARP
(Table 1). The incidence of RRT in the age group 20-74 years was 137 PMARP and varied
considerably between countries and regions, ranging from 75 PMARP in Estonia to 175 PMARP in
French-speaking Belgium. However, the difference between registries was much greater in the age
group 75 years or older with the incidence of RRT ranging from 157 PMARP in Estonia to 924
PMARP in Dutch-speaking Belgium (Figure 1). The variation further increased in the age group 85
years or older, in which the incidence ranged from 27 PMARP in Spain (Cantabria) to 755 PMARP
in Dutch-speaking Belgium. In the age group 75 years or older, the incidence rate ratio of RRT
between men and women varied markedly, from 1.5 in Bosnia and Herzegovina to 4.4 in the
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74 years was considerably larger in registries with higher incidence of RRT in the elderly (Table 1).
Patient characteristics
Table 2 shows the characteristics of the patients in registries with low and high incidence of RRT.
Twenty-two registries and 13 033 patients were included in the low-incidence group and seven
registries and 25 424 patients in the high-incidence group. The median age of the entire cohort of
patients 75 years or older was 80.5 (IQR 6.2) years at start of RRT. Patients from the low incidence
areas were younger and more frequently had peritoneal dialysis as the initial treatment modality.
Sex and BMI distributions were almost similar in both incidence groups. Hypertension was a more
common cause of ESRD in the high-incidence compared with the low-incidence group. The rate of
kidney transplantation within one year from the onset of RRT was small in this cohort of elderly
patients, but was greater in the low- than the high-incidence group.
Registries with incidence of RRT in elderly patients in the upper range showed a significantly
higher median age at the initiation of RRT, whereas the ratio between males and females, the life
expectancy at birth, or GDP per capita of the area did not correlate with RRT incidence (Figure 2).
Survival
Cardiovascular cause of death was most common in both incidence groups, 28.0% in the low-
incidence group and 31.4% in the high-inceidence group. The distribution of causes of death was
different between the low- and high-incidence groups (P < 0.001). The difference was mainly due
to higher percentage of patients dying from cardiovascular and cerebrovascular causes in the high
incidence registries and lower percentage of patients dying due to suicide or refusal or withdrawal
of treatment.
Survival among the 36 807 patients aged 75 years or older was worse in the higher age groups.
One-year survival from the onset of RRT was 74% (95% CI 73—74%) in the whole cohort and for
the age groups 75-79 years, 80-84 years and 85 years or older the survival rate was 78% (95% CI
77—78%), 73% (95% CI 72—74%) and 66% (95% CI 65—68%) (P < 0.001), respectively. Among
patients older than 75 years, the 1-year survival was 76% (95% CI 75—76%) in the low-incidence
group and 73% (95% CI 72—73%) in the high-incidence group (P = 0.04) (Figure 3).
The relative risk of death was 1.03 (95% CI 1.002—1.065) in the high- compared with the low-
incidence group. After adjustment for age and gender, there was no difference in survival between
the low- and high-incidence groups (RR 0.97; 95% CI 0.94—1.00). Further adjustment for initial
RRT modality and the cause of ESRD did not affect the relative risk of death (RR 1.00; 95% CI
0.97—1.03).
Comorbidities
A total of 10 714 patients from 12 registries provided comorbidity data at the start of RRT. Basic
characteristics of patients in registries with low and high incidence of RRT were similar compared
to the whole cohort. Diabetes, ischaemic heart disease, cerebrovascular disease and malignancies
were more common among patients in the low-incidence group, whereas peripheral vascular
disease was more common in the high-incidence group (Table 2). In the low-incidence group, 76%
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incidence group (P < 0.001).
In survival analysis of patients who had data available on all five reported comorbidities (N =
9014), the risk of death was lower in the high-incidence group (RR 0.76; 95% CI 0.71—0.80) than in
the low-incidence group. All of the comorbidities and higher age at onset of RRT were associated
with worse survival. When age at onset of RRT, sex and comorbidities were added into the
multivariable model, the relative risk of death among patients in the high-incidence group did not
change (RR 0.75; 95%CI 0.71—0.79).
DISCUSSION
This study showed the incidence of RRT to vary significantly between European countries.
Strikingly, in age group 75 years or older the difference between the countries with the highest
and lowest incidence was almost sixfold, whereas among patients aged 20—74-years the
difference was only twofold. We were not able to find any plausible explanations for this
difference. Notably, there was no association between wealth, life expectancy, comorbidities or
other patient characteristics and the incidence of RRT among the elderly. The only exception was
age at the onset of RRT, which was greater in high-incidence areas. Our study also revealed that
survival of the elderly patients was remarkably similar in the low- and high-incidence areas. In the
subset of patients with available comorbidity data, the risk of death was higher in the low-
incidence group, and this did not change after adjustments. This reflects the fact that the
comorbidities, all of which were associated with worse survival, were surprisingly more common
in the low-incidence group, despite the older age in the high-incidence group. This is in line with a
study from France showing lower comorbidity among older age groups of dialysis patients [12].
Taken together, our findings suggest that differences in patient selection and timing of RRT may
account for at least part of the observed variation in incidence.
The main strength of this study is the large and comprehensive cohort from the 29 registries that
includes complete data on age, sex, primary renal diagnosis, initial RRT modality and survival.
Hence, selection bias was minimal in the main analyses. By contrast, data on comorbidities were
available from only 12 registries and were complete for only 84% of patients. Among these
patients the risk of death was higher in the low-incidence registries in contrast to the results from
the whole study population. This limitation may have introduced a bias into the analyses. The
higher incidence of comorbidities in the low-incidence registries might reflect a higher prevalence
of comorbid conditions in the general population in these countries. There could also be
differences in the practice of collecting and reporting comorbidity data, or in evaluating predialytic
patients for comorbidities between countries and regions. The proportion of patients who receive
conservative treatment of kidney failure might also vary. The timing of the onset of RRT is likely to
have an impact on the incidence of RRT among the elderly as their mortality rate is high and death
is an important competing risk for starting dialysis [13-15]. Unfortunately we did not have
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predialytic renal disease to explore this issue. Notably, early start of RRT has not been shown to
improve survival [16], and in fact an early start has been reported to associate with worse survival
in elderly patients because of their high rate of comorbidity [17,18]. Variations in practice of
acceptance of patients into RRT and conservative management, profit vs. non-profit haemodialysis
facilities, pre-dialysis management, and competing mortality may all play an important role in
explaining differences in RRT incidence, but these were not evaluated in this study.
Caskey and colleagues reported that GDP per capita and money spent on health care and dialysis
facilities were positively associated with RRT incidence rates across 46 countries worldwide [19].
They also showed that higher incidence of RRT associates with private for-profit haemodialysis
facilities in developed countries, which is in line with a study of conservative care for ESRD in 11
European countries [20]. We were unable to show an association between GDP per capita and RRT
incidence in the aging population. This may potentially be due to smaller differences in GDP
between the countries in our analysis. Furthermore, Visser and colleagues showed that the higher
incidence of RRT in the elderly in Flanders compared with the Netherlands does not seem to be
due to a more restrictive referral policy or lower access to RRT in the Netherlands. They suggested
that the difference was more likely due to differences in comorbidity and life style [21,22].
The differences in RRT incidence among the elderly could be partly explained by diverse usage of
conservative management in the care of patients with ESRD. A study from the UK revealed that
there is much variation in the way conservative management of ESRD is provided in 67 UK renal
units [23]. This variability may be even more notable between countries. Several studies have
reported that dialysis improves the survival of elderly patients [24-26]. In addition, better
management of patients during the progression of chronic kidney disease could reduce the
number of comorbidities and increase the number of healthier elderly patients who benefit from
dialysis [27]. However, when older age is combined with greater comorbidity, the prognosis is
similar with dialysis and conservative management [9,28,29]. Despite this, the level of comorbidity
had no effect on the decision to initiate dialysis in elderly patients in a recent study from United
States [30]. Although dialysis improves the survival of elderly patients with ESRD, the treatment is
associated with higher rates of hospitalization [31]. This together with the burden of dialysis
therapy may explain why declining quality of life is frequently observed in these patients [25,32].
In fact, the quality of life is often better preserved in patients receiving conservative care for ESRD
[24]. Consequently, dialysis should not be expected to improve the quality of life in elderly
patients with comorbidity [8,25]. Information provided to patients by nephrologists and other
renal unit staff plays an important role when older adults are choosing between dialysis and
conservative management [33], but according to the study from the Netherlands the decision
seems to be based on personal values, beliefs and feelings toward life, suffering, and expected
difficulties on RRT, rather than on the effectiveness of the treatment [34]. Dialysis is expensive,
especially among elderly, and is estimated to cost up to 90 000 euros annually for each patient
[35]. Therefore, the decision to start dialysis in an elderly patient with substantial comorbidity
should only be made after careful consideration and the patient should be involved in the
decision-making [36,37].
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This European study shows that in areas with a high incidence of RRT among the elderly, the age at
RRT start was slightly higher, while age-adjusted survival was similar compared with areas with
low incidence. Data on comorbidities were available only for a subset of patients and
comorbidities were more common in patients from the low-incidence areas. Factors explaining the
differences in RRT incidence could not be elucidated and, therefore further studies are reqiured.
However, our findings may suggest that differences in patient selection and timing of RRT may
explain some of the variation in incidence. An inappropriately high acceptance rate to dialysis is
very costly for the society and may not improve survival or quality of life of patients. On the other
hand, the criteria for initiating dialysis in elderly might be too strict in the low-incidence countries
and regions. The fact that low or high incidence of RRT among the elderly is not associated with
survival raises the question which policy is correct. More information is needed to guide treatment
decisions for ESRD in the elderly.
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Figure 1. Incidence of renal replacement therapy per million age-related population in 2010-2013, by age
group
Data from Bosnia and Herzegovina and Serbia were available in 2011-2013, from Spain region of Murcia in 2012-2013, and from Estonia in 2013.
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Table 1. Incidence of renal replacement therapy per year between 2010 and 2013 per million age-
related population, by age group
Number of
patients ≥75
years
RRT incidence of
patients ≥75 years
PMARP
RRT incidence of
patients ≥85 years
PMARP
≥75 / 20-74
years1
Male /
Female2
All Female Male All Female Male All All All
Belgium (Dutch-peaking) 2169 637 1361 924 478 632 755 6.1 2.1
Greece 3870 630 1223 882 559 711 751 5.3 1.9
Belgium (French-speaking) 1290 465 1532 846 348 511 620 4.8 3.3
France 15587 413 1128 678 338 482 574 4.8 2.7
Spain (Catalonia) 1404 325 858 529 138 250 268 4.0 2.6
Bosnia and Herzegovina 213 444 646 528 158 189 247 3.8 1.5
Spain (Valencian region) 891 338 800 523 149 195 231 3.9 2.4
Austria 1327 310 804 489 172 189 265 3.5 2.6
the Netherlands 2177 270 751 457 126 185 219 3.8 2.8
Denmark 721 257 742 451 161 242 276 3.6 2.9
Iceland 33 324 584 436 154 77 146 5.1 1.8
Spain (Andalusia) 1040 290 606 414 99 163 177 3.4 2.1
Spain (Community of Madrid) 823 239 710 413 59 168 160 3.8 3.0
Norway 553 208 679 392 113 178 199 3.6 3.3
Spain (Aragon) 236 209 656 389 42 85 84 3.1 3.1
Sweden 1247 219 635 387 112 180 194 3.2 2.9
Spain (Asturias) 196 204 619 358 84 159 170 2.8 3.0
Spain (Galicia) 485 191 613 353 64 94 109 2.6 3.2
Spain (Region of Murcia) 70 238 471 332 58 29 58 2.8 2.0
Spain (Castile and León) 446 193 537 331 95 147 159 3.1 2.8
Spain (Extremadura) 152 194 522 324 88 100 125 2.6 2.7
Spain (Castile-La Mancha) 253 227 407 302 13 94 68 2.9 1.8
Spain (Basque country) 272 131 577 299 46 64 78 2.6 4.4
Serbia 475 215 416 290 83 113 128 1.7 1.9
Romania 1650 174 447 282 45 96 91 1.8 2.6
United Kingdom, Scotland 448 181 409 270 64 44 73 2.5 2.3
Spain (Cantabria) 53 110 383 213 20 20 27 1.8 3.5
Finland 358 104 372 201 23 49 53 2.1 3.6
Estonia 18 109 280 157 0 48 38 2.1 2.6
All 38457 335 859 536 224 320 373 3.9 2.6
Data from Bosnia and Herzegovina and Serbia were available in 2011-2013, from Spain region of Murcia in 2012-2013, and from Estonia in 2013.
RRT, renal replacement therapy.
PMARP, per million age related population.
1Ratio of RRT incidence in ≥75 and 20-74 years old patients.
2Ratio of RRT incidence in male and female ≥75 years old.
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Table 2. Characteristics of patients 75 years or older, divided into low- and high-incidence renal
replacement therapy groups
Low incidence
(≤500 PMARP)
High incidence
(>500 PMARP) P-value
Number of patients 13 033 25 424
Male (%) 62.2 61.2 0.045
Median age (years) 79.6 (IQR 5.4) 81.1 (IQR 6.5) <0.001
85 years or older (%) 11.6 22.5 <0.001
Median Body mass index1 25.3 (IQR 5.7) 25.7 (IQR 6.1) 0.050
Initial RRT modality
Haemodialysis (%) 87.3 90.4 <0.001
Peritoneal dialysis (%) 12.5 8.7
Kidney transplantation (%) 0.2 0.1
Missing (%) 0.0 0.7
Kidney transplantation within one
year (%) 0.7 0.3 <0.001
Primary renal disease
Glomerulonephritis (%) 6.5 5.4 <0.001
Pyelonephritis (%) 5.4 4.2
Polycystic renal disease (%) 2.2 1.9
Diabetic nephropathy (%) 17.6 19.7
Hypertension (%) 18.9 29.6
Vascular disease (%) 8.4 3.3
Other (%) 15.8 14.6
Chronic kidney disease NAS (%) 24.1 21.2
Missing (%) 1.1 0.0
Comorbidity2
Diabetes (%) 36.8 30.9 <0.001
Ischemic heart disease (%) 36.1 32.6 <0.001
Peripheral vascular disease (%) 21.5 25.3 <0.001
Cerebrovascular disease (%) 19.9 16.1 <0.001
Malignancy (%) 22.4 16.5 <0.001
Mean life expectancy at birth (years) 81.6 (IQR 2.0) 81.3 (IQR 1.8) 0.64
Mean gross domestic product per
capita (US dollars)
26644
(IQR 17325)
23966
(IQR 15100) 0.82
PMARP, per million age related population; NAS, Aetiology uncertain / unknown; IQR, interquartile range
1Body mass index could be calculated for 2015 patients in the low-incidence group and 1837 patients in the high-
incidence group.
2Available from Austria, Dutch- and French-speaking Belgium, Denmark, Finland, Iceland, Norway, Sweden, and the
Spanish regions of Aragon, Catalonia, Galicia, and Valencia, 4960 patients in the low-incidence group and 5754
patients in the high-incidence group.
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Figure 2. Association between explanatory factors and incidence of renal replacement therapy in
patients 75 years or older
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Figure 3. Survival from onset of renal replacement therapy, by low- and high-incidence renal
replacement therapy groups
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